LATEST TWEETS - CURATED BY HASH FINANCE

FDA Gives Green Light to IND for Berubicin for Glioblastoma Multiforme https://t.co/EgBwt5g5kc via @onclive… https://t.co/AerGAWdAy0
$SB CEO To Announce An Open Market Share Buy Back Program To Begin Un The Next 2 Weeks https://t.co/Mv3xmUrTi2 https://t.co/BTTO1Lmrhv
$JFIN CEO To Announce An Open Market Share Buy Back Program To Begin Un The Next 2 Weeks https://t.co/Mv3xmUrTi2 https://t.co/H7ACphEbyH
@senwarren @senmarkey @DrPatSoonShiong In the recent January 2021 $IBRX S-4 filing on page 220 - Soon Shiong is us… https://t.co/55nB5vdFf1
From the S-4 Given the unique characteristics of Aldoxorubicin, with the ability to cross the blood-brain barrier,… https://t.co/oOWYC59t3i
@SenWarren @SenMarkey @DrPatSoonShiong bought rights to Aldoxorubicin in 2017 immediately b4 $CYTR was going to fil… https://t.co/Lxsc3m17q4
$CYTR the failure of @DrPatSoonShiong can be measured in how many patients were treated with doxorubicin while less… https://t.co/IXRe5CbilC
$SBUX CEO To Announce An Open Market Share Buy Back Program To Begin Un The Next 2 Weeks https://t.co/Mv3xmUrTi2 https://t.co/wWfbluXYAn
page 219 S4 $CYTR We are developing a protocol to treat recurrent glioblastoma using Aldoxorubicin. Unlike doxorubi… https://t.co/8wYbMP2VQc
$CYTR Waiting for buy signal on CYTR with UltraAlgo https://t.co/oe45YmZuA2
@DrPatSoonShiong hey doc how come you didn't tell @davidfaber @RiggsReport @MorganLBrennan about your patent for Al… https://t.co/OLWtm3fA4m